Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 2Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Thoracic 1Sarcoma 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Melanoma 23Neoplasm Metastasis 11Leukemia, Myeloid, Acute 11Pancreatic Neoplasms 7Ovarian Neoplasms 7Carcinoma, Renal Cell 7Leukemia 6Kidney Neoplasms 6Breast Neoplasms 6Uterine Cervical Neoplasms 5Stomach Neoplasms 5Lymphoma 5Carcinoma, Non-Small-Cell Lung 5Neuroblastoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Colonic Neoplasms 4Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Leukemia, Myelomonocytic, Chronic 3Gastrointestinal Neoplasms 3Congenital Abnormalities 3Vulvar Neoplasms 2Vaginal Neoplasms 2Uveal Melanoma 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2

Interventions

pembrolizumab 30Nivolumab 15Paclitaxel 13Cyclophosphamide 12Carboplatin 12sacituzumab govitecan 8Cisplatin 8Capecitabine 7130-nm albumin-bound paclitaxel 7Gemcitabine 6fludarabine 5durvalumab 5avelumab 5atezolizumab 5Magnetic Resonance Spectroscopy 5Ipilimumab 5Biopsy 5camrelizumab 4Specimen Handling 4Interleukin-2 4Injections 4Immune Checkpoint Inhibitors 4Docetaxel 4toripalimab 3talazoparib 3Leucovorin 3Everolimus 3Clinical Trials, Phase II as Topic 3Bevacizumab 3yeast-CEA vaccine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Triple Negative Breast Neoplasms × aldesleukin × Clear all
NCT05296564 2025-10-02

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Hadassah Medical Organization

Phase 1/2 Recruiting
3 enrolled
BreastCNSDermatologicGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Sarcoma, Synovial, Triple Negative Breast Neoplasms

NCT05821686 2025-02-12

Efficacy of Interleukin-2 in Triple Negative Breast Cancer

Nova Scotia Health Authority

Phase 1/2 Not yet recruiting
10 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡